D. Gjaltema

发表

Can 'extrafine' dry powder aerosols improve lung deposition?

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

‘ extrafine ’ dry powder aerosols improve lung deposition ? q

H. Frijlink, P. Hagedoorn, A. D. Boer, 2015 .

Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler

G. Bolhuis, P. Hagedoorn, G. Bolhuis, 1997 .

Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy.

D. Barends, P. Zanen, A. D. de Boer, 2002, International journal of pharmaceutics.

Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2009, Respiratory medicine.

Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2006, International journal of pharmaceutics.

Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler

H. Frijlink, P. Hagedoorn, A. D. Boer, 2013 .

Design and application of a new modular adapter for laser diffraction characterisation of inhalation aerosols

W. Witt, P. Hagedoorn, M. Schaller, 2005 .

Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols.

W. Witt, A. D. de Boer, P. Hagedoorn, 2002, International journal of pharmaceutics.

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 1999, International journal of pharmaceutics.

Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2006, International journal of pharmaceutics.

Chapter 9 Air classifier technology ( ACT ) in dry powder inhalation Part 3 : Design and development of an air classifier family for the Novolizer ® multi-dose dry powder inhaler

P. Hagedoorn, H. W. Frijlink, D. Gjaltema, 2005 .

Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.

A. D. de Boer, P. Hagedoorn, H. W. Frijlink, 2004, Die Pharmazie.

Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2003, International journal of pharmaceutics.

The rate of drug particle detachment from carrier crystals in an air classifier based dry powder inhaler

P. Hagedoorn, H. W. Frijlink, D. Gjaltema, 2005 .

A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation.

H. Frijlink, A. D. de Boer, B. Dickhoff, 2005, International journal of pharmaceutics.

Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2003, International journal of pharmaceutics.

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

A. D. de Boer, P. Hagedoorn, H. Heijerman, 1999, International journal of pharmaceutics.

Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.

P Hagedoorn, A H de Boer, H. Frijlink, 2002, International journal of pharmaceutics.

Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers part 2: effect of peak flow rate (pifr) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers

P. Hagedoorn, de Anne Boer, Doetie Gjaltema, 1996 .